

## Battle of the Bulge: A Review of Weight Loss Medications and Supplements

### Appendix A: References

Apovian CM, Aronne LJ, Bessesen DH, et al. Pharmacological Management of Obesity: An Endocrine Society clinical practical guideline. *J Clin Endocrinol Metab.* 2015;100(2):342-362.

Arena Pharmaceuticals GmbH. Belviq/Belviq XR [package insert]. Zonfingen, Switzerland: 2017, November.

Burguera B, Ali KF, Brito JP. Antiobesity drugs in the management of T2DM: a shift in thinking? *Clev J Med.* 2017;84(1):S39-S46.

Centers for Disease Control and Prevention. Prevalence of overweight, obesity, and extreme obesity among adults: obesity prevalence maps. (<http://www.cdc.gov/obesity/data/prevalence-maps.html>). Accessed October 10, 2017.

Dombrowski SU, Knittle K, Avenell A, et al. Long term maintenance of weight loss with non-surgical interventions in obese adults: systematic review and meta-analyses of randomized controlled trials. *BMJ.* 2014;348:g2646-58.

Egras AM, Hamilton WR, Lenz TL. An evidence based review of fat modifying supplemental weight loss products. *J Obes.* 2011. Doi:10.1155/2011/297315. Epub 2010 Aug 10.

Falzon CC, Balabanova A. Phytotherapy: An Introduction to Herbal Medicine. *Prim Care.* 2017;44(2):217-227.

Garvey WT, Mchanick JI, Brett EM, et al. American Association of Clinical Endocrinologists and American College of Endocrinology comprehensive practice guidelines for medical care of patients with obesity. *Endocr Pract.* 2016;22 Suppl 3:1-203.

Genentech USA, Inc. Xenical [package insert]. South San Francisco, CA: 2016, August.

Greenberg AS, Obin MS. Obesity and the role of adipose tissue in inflammation and metabolism. *Am J Clin Nutr.* 2006;83:461S-5S.

Hainer V. Overview of new antiobesity drugs. *Expert Opin Pharmacother.* 2014;15(14):1975-78.

Hall DMB, Cole TJ. What use is the BMI? *Arch Dis Child.* 2006;91(4):283-286.

Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American college of cardiology/ American Heart Association task force on practice guidelines and The Obesity Society. *Circulation.* 2014;129(25 Suppl 2):S102-38.

Kang JG, Park CY. Anti-Obesity Drugs: A review about their effects and safety. *Diabetes Metab J*. 2012; 36(1):13-25.

Khera R, Murad MH, Chandar AK, et al. Association of pharmacological treatments for obesity with weight loss and adverse events: A systematic review and meta-analysis. *JAMA*. 2016; 315(22):2424-2434.

Novo Nordisk Inc. Saxenda [package insert]. Plainsboro, NJ: 2017, April.

Orexigen Therapeutics, Inc. Contrave [package insert]. La Jolla, CA:2017, May.

Ogden CL, Carroll MD, Kit BK, and Flegal KM. Prevalence of obesity among adults: United States, 2011-2012. *NCHS Data Brief*. 2013;131:1-8.

Pittler MH, Ernst E. Dietary supplements for body-weight reduction: a systematic review. *Am J Clin Nutr*. 2004;79:529-36.

Rodgers RJ, Tschop MH, Wilding JPH. Anti-obesity drugs: past, present, and future. *Dis Model Mech*. 2012; 5(5):621-626.

Smith SM, Meyer M, and Trinkley KE. Phentermine/topiramate for the treatment of obesity. *Ann Pharmacother*. 2013;47(3):340-49.

Stohs SJ, Badmaev V. A review of natural stimulant and non-stimulant thermogenic agents. *Phytother Res*. 2016;30(5):732-40.

Tainted Products Marketed as Dietary Supplements. US Food and Drug Administration Medication Health Fraud Page. ([https://www.accessdata.fda.gov/scripts/sda/sdNavigation.cfm?sd=tainted\\_supplements\\_cder](https://www.accessdata.fda.gov/scripts/sda/sdNavigation.cfm?sd=tainted_supplements_cder)). Accessed 20 November 2017.

Trust for America's Health and the Robert Wood Johnson Foundation. Updated 31 August 2017. Adult obesity in the United States. (<https://stateofobesity.org/adult-obesity/>). Accessed 20 November 2017.

Vivus, Inc. Qsymia [package insert]. Mountain View, CA: 2014, October.

World Health Organization. Obesity and overweight fact sheet no 311. (<http://www.who.int/mediacentre/factsheets/fs311/en/>). Accessed September 27, 2017.